Denosumab

Standard

Denosumab : a potential new and innovative treatment option for aneurysmal bone cysts. / Lange, Tobias; Stehling, Christoph; Fröhlich, Birgit; Klingenhöfer, Mark; Kunkel, Philip; Schneppenheim, Reinhard; Escherich, Gabriele; Gosheger, Georg; Hardes, Jendrik; Jürgens, Heribert; Schulte, Tobias L.

In: EUR SPINE J, Vol. 22, No. 6, 01.06.2013, p. 1417-22.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Lange, T, Stehling, C, Fröhlich, B, Klingenhöfer, M, Kunkel, P, Schneppenheim, R, Escherich, G, Gosheger, G, Hardes, J, Jürgens, H & Schulte, TL 2013, 'Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts', EUR SPINE J, vol. 22, no. 6, pp. 1417-22. https://doi.org/10.1007/s00586-013-2715-7

APA

Lange, T., Stehling, C., Fröhlich, B., Klingenhöfer, M., Kunkel, P., Schneppenheim, R., Escherich, G., Gosheger, G., Hardes, J., Jürgens, H., & Schulte, T. L. (2013). Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. EUR SPINE J, 22(6), 1417-22. https://doi.org/10.1007/s00586-013-2715-7

Vancouver

Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. EUR SPINE J. 2013 Jun 1;22(6):1417-22. https://doi.org/10.1007/s00586-013-2715-7

Bibtex

@article{7009fe5e514a4992af019fad50f1bcfc,
title = "Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts",
abstract = "INTRODUCTION: Aneurysmal bone cysts (ABCs) are expansive and destructive lesions positive for osteoclast markers, resembling benign giant cell tumors (GCTs). Treatment options include surgical resection, curettage and cavity filling, embolization, injection of fibrosing agents, or radiotherapy. Particularly in children and adolescents with spinal ABCs, these options may be unsatisfactory, and innovative forms of treatment are needed. Denosumab is a human monoclonal antibody that inhibits osteoclast function by blocking the cytokine receptor activator of the nuclear factor-kappa B ligand. Satisfactory results with denosumab in treating GCTs and immunohistochemical similarities suggest that it may also have positive effects on ABCs.METHODS AND RESULTS: This report is the first description of the therapeutic use of denosumab in two patients with spinal ABCs. Two boys (aged 8 and 11) had recurrent ABCs at C5 after surgery with intralesional tumor resection. Treatment options were discussed by the interdisciplinary tumor board. Arterial embolization was attempted, but failed due to an absence of appropriate afferent arteries. After the families had received extensive information and provided written consent, denosumab therapy was initiated as an individualized treatment, despite the absence as yet of scientific evidence. After the start of denosumab therapy, both patients recovered from pain and neurologic symptoms significantly and are now in a healthy condition with no severe side effects. Magnetic resonance imaging check-ups after 2 or 4 months of denosumab treatment, respectively, showed tumor regression in both patients.DISCUSSION: Longer follow-up and clinical studies are warranted to establish the value of denosumab in the treatment of ABCs.",
keywords = "Antibodies, Monoclonal, Humanized, Bone Cysts, Aneurysmal, Child, Humans, Magnetic Resonance Imaging, Male, Spinal Diseases",
author = "Tobias Lange and Christoph Stehling and Birgit Fr{\"o}hlich and Mark Klingenh{\"o}fer and Philip Kunkel and Reinhard Schneppenheim and Gabriele Escherich and Georg Gosheger and Jendrik Hardes and Heribert J{\"u}rgens and Schulte, {Tobias L}",
year = "2013",
month = jun,
day = "1",
doi = "10.1007/s00586-013-2715-7",
language = "English",
volume = "22",
pages = "1417--22",
journal = "EUR SPINE J",
issn = "0940-6719",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Denosumab

T2 - a potential new and innovative treatment option for aneurysmal bone cysts

AU - Lange, Tobias

AU - Stehling, Christoph

AU - Fröhlich, Birgit

AU - Klingenhöfer, Mark

AU - Kunkel, Philip

AU - Schneppenheim, Reinhard

AU - Escherich, Gabriele

AU - Gosheger, Georg

AU - Hardes, Jendrik

AU - Jürgens, Heribert

AU - Schulte, Tobias L

PY - 2013/6/1

Y1 - 2013/6/1

N2 - INTRODUCTION: Aneurysmal bone cysts (ABCs) are expansive and destructive lesions positive for osteoclast markers, resembling benign giant cell tumors (GCTs). Treatment options include surgical resection, curettage and cavity filling, embolization, injection of fibrosing agents, or radiotherapy. Particularly in children and adolescents with spinal ABCs, these options may be unsatisfactory, and innovative forms of treatment are needed. Denosumab is a human monoclonal antibody that inhibits osteoclast function by blocking the cytokine receptor activator of the nuclear factor-kappa B ligand. Satisfactory results with denosumab in treating GCTs and immunohistochemical similarities suggest that it may also have positive effects on ABCs.METHODS AND RESULTS: This report is the first description of the therapeutic use of denosumab in two patients with spinal ABCs. Two boys (aged 8 and 11) had recurrent ABCs at C5 after surgery with intralesional tumor resection. Treatment options were discussed by the interdisciplinary tumor board. Arterial embolization was attempted, but failed due to an absence of appropriate afferent arteries. After the families had received extensive information and provided written consent, denosumab therapy was initiated as an individualized treatment, despite the absence as yet of scientific evidence. After the start of denosumab therapy, both patients recovered from pain and neurologic symptoms significantly and are now in a healthy condition with no severe side effects. Magnetic resonance imaging check-ups after 2 or 4 months of denosumab treatment, respectively, showed tumor regression in both patients.DISCUSSION: Longer follow-up and clinical studies are warranted to establish the value of denosumab in the treatment of ABCs.

AB - INTRODUCTION: Aneurysmal bone cysts (ABCs) are expansive and destructive lesions positive for osteoclast markers, resembling benign giant cell tumors (GCTs). Treatment options include surgical resection, curettage and cavity filling, embolization, injection of fibrosing agents, or radiotherapy. Particularly in children and adolescents with spinal ABCs, these options may be unsatisfactory, and innovative forms of treatment are needed. Denosumab is a human monoclonal antibody that inhibits osteoclast function by blocking the cytokine receptor activator of the nuclear factor-kappa B ligand. Satisfactory results with denosumab in treating GCTs and immunohistochemical similarities suggest that it may also have positive effects on ABCs.METHODS AND RESULTS: This report is the first description of the therapeutic use of denosumab in two patients with spinal ABCs. Two boys (aged 8 and 11) had recurrent ABCs at C5 after surgery with intralesional tumor resection. Treatment options were discussed by the interdisciplinary tumor board. Arterial embolization was attempted, but failed due to an absence of appropriate afferent arteries. After the families had received extensive information and provided written consent, denosumab therapy was initiated as an individualized treatment, despite the absence as yet of scientific evidence. After the start of denosumab therapy, both patients recovered from pain and neurologic symptoms significantly and are now in a healthy condition with no severe side effects. Magnetic resonance imaging check-ups after 2 or 4 months of denosumab treatment, respectively, showed tumor regression in both patients.DISCUSSION: Longer follow-up and clinical studies are warranted to establish the value of denosumab in the treatment of ABCs.

KW - Antibodies, Monoclonal, Humanized

KW - Bone Cysts, Aneurysmal

KW - Child

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Spinal Diseases

U2 - 10.1007/s00586-013-2715-7

DO - 10.1007/s00586-013-2715-7

M3 - SCORING: Journal article

C2 - 23455951

VL - 22

SP - 1417

EP - 1422

JO - EUR SPINE J

JF - EUR SPINE J

SN - 0940-6719

IS - 6

ER -